Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $35.5400 per ADS
- Total Volume Acquired: 23,771.796 ADSs (comprising 23,206.796 via the Executive Supplemental Savings Plan and 565 via the 401(k) Plan)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses the acquisition of company stock by an executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific transaction executed on March 12, 2021, on the New York Stock Exchange (XNYS).
Key Facts for Investor Verification
- Executive Involved: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisitions of ADSs through employee benefit plans (Executive Supplemental Savings Plan and 401(k) Plan).
- Transaction Date: March 12, 2021.
- Market Price: The shares were acquired at $35.5400.
- Reporting Limitation: This filing does not contain quarterly or annual financial performance data.